DX & VX signs 3 billion-won precision medical genome analysis contract

Dx & Vx said Friday that it has signed a 3 billion won ($2.38 million) contract with COREE to provide precision medical genome analysis service.

The research project began this year and aimed to turn 10 thousand or more immunocyte profiling results into big data for three years.

COREE, which focuses on the health industry, has also invested in a mother-and-child clinical trial at the Beijing Union Hospital and a metabolic chronic disease clinical study at Italy’s Gemelli Hospital.

The company’s investment into Dx & Vx’s genomic analysis service was aimed at analyzing biological data related to infectious diseases and developing and commercializing diagnoses and customized treatments.

the past year, we formed four cohort groups and conducted 3,156 immunocyte-profiled whole genome sequencing genes and immunocyte-related genomic analysis. The database will be used to develop biomarkers for customized immunotherapies based on Oxford Vacmedix’s clinical trial results of anticancer vaccines,” CEP Park Sang-tae said.